Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage

The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced

Informations de copyright

Copyright © 2023 Goldman, Sholl, Dacic, Fishbein, Murciano-Goroff, Rajaram, Szymczak, Szpurka, Chao and Drilon.

Déclaration de conflit d'intérêts

Author JG receives research funding from Eli Lilly and Company. LS consults with Astra Zeneca, Genentech, Eli Lilly and Company, and GV20 Therapeutics. She receives research funding from Bristol Myers Squibb and Genentech. SD is a consultant with Astra Zeneca and receives honoraria from Janssen, Takeda, and Merck. YM-G’s work was supported in part by a National Cancer Institute/ National Institutes of Health Cancer Center Support Grant (P30CA008748) to Memorial Sloan Kettering Cancer Center. YM-G reports travel, accommodation, and expenses from AstraZeneca and Loxo Oncology/Eli Lilly; food/beverages from Endeavor Biomedicines; and honoraria from Virology Education and Projects in Knowledge for a CME program funded by an educational grant from Amgen. She acknowledges associated research funding to the institution from Mirati Therapeutics, Loxo Oncology at Eli Lilly and Company, Elucida Oncology, Taiho Oncology, Hengrui USA, Ltd./Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, and Endeavor Biomedicines. She acknowledges royalties from Rutgers University Press and Wolters Kluwer. YM-G acknowledges receipt of funding from the Andrew Sabin Family Foundation as well as training through an institutional K30 grant from the NIH CTSA UL1TR00457. She has received funding from a Kristina M. Day Young Investigator Award from Conquer Cancer, the ASCO Foundation, endowed by Dr. Charles M. Baum and Carol A. Baum. She is also funded by the Fiona and Stanley Druckenmiller Center for Lung Cancer Research and a Paul Calabresi Career Development Award for Clinical Oncology NIH/NCI K12 CA184746. RR is a consultant with Johnson and Johnson. SS, AS, and BC are employed by Eli Lilly and Company. AD has stocks in TreeLine Bio. He receives honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, PeerView Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, and Remedica Ltd. He is in a consulting or advisory role at Ignyta/Genentech/Roche, Loxo/ Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd., mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc., AiCME, i3 Health, and MonteRosa. He acknowledges research funding from Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, and PharmaMar. His patents, royalties, and other intellectual property include Selpercatinib-Osimertinib filed/pending, Wolters Kluwer, Merck, Puma, Merus, and Boehringer Ingelheim. AD is also supported by grants from the National Cancer Institute/National Institutes of Health (P30CA008748, 1R01CA251591001A1, 1R01CA273224-01) and Lungevity. The remaining author declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Loxo Oncology, which is now called Loxo@Lilly. The funder had the following involvement in the study: collected, analyzed, and interpreted the trial data in collaboration with the authors. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.